Home » Topics » BioWorld Science

BioWorld Science
RSS

Panitumumab-IRDye800 in phase II for metastatic lymph node identification in HNSCC

Sep. 3, 2019

POU3F3 disruptions linked to neurodevelopmental disorder

Sep. 3, 2019

Checkpoint blockade protects from homeostatic inhibition and amplifies antitumor T-cell responses

Sep. 3, 2019

Preclinical characterization of the novel covalent Inhibitor of CDK7, SY-1365

Sep. 3, 2019

Phase II data reported for P2Y12 inhibitor selatogrel in CAD patients

Sep. 2, 2019

TLR4 agonist INI-2004 as immunostimulant for the treatment of infectious diseases

Sep. 2, 2019

A reverse engineering approach for in vitro modeling of the human eye

Sep. 2, 2019

One and done: Engineered oncolytic virus can invite T cells, feed them lunch

Sep. 2, 2019

New human antibody targeting PSMA inhibits prostate cancer tumor growth

Sep. 2, 2019

Chinese investigators present adenosine A2A receptor antagonists

Sep. 2, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.